Cosmederm launches new ‘calming’ product

SAN DIEGO — Cosmederm Bioscience’s TriCalm OTC itch-relief solution was recognized in May by the journal Clinical, Cosmetic and Investigational Dermatology, which published a study finding that Cosmederm’s solution was superior to diphenhydramine 2% and hydrocortisone 1%.

(Click here to read the full Category Review.)



That superior efficacy may translate into a significant sales story going forward. As of April 19, TriCalm 52 week sales totaled 5.2 million on growth of 276.5% across total U.S. multi-outlets, according to IRI.



“The results of this study are a testament to TriCalm’s value as the most effective over-the-counter itch relief treatment,” Sean Edwards, president and CEO of Cosmederm Bioscience, said when announcing the results last month. “They validate our claim that TriCalm is more effective at relieving itch than hydrocortisone 1%, providing fast-acting itch relief without the potential side effects of steroid-based creams.”



Cosmederm Bioscience is looking to bring two new anti-itch solutions to the marketplace for the coming review season, said Justin Brown, Cosmederm Bioscience VP sales. “But we’re in development [of other new products]. We anticipate by the end of the year having 10 really unique formulations, everything ranging from psoriasis products to something as simple as a daily sensitive skin lotion.”



TriCalm has a very aggressive integrated marketing and advertising budget that includes TV, radio, print, social media, internet and doctor initiatives, and is represented by David Biernbaum.